Humira
Humira is an immunosuppressant that has proven to help treat a variety of immune-related conditions, such as Crohn’s disease, rheumatoid arthritis, and the most common form of psoriasis.
Despite its clear value, Humira has become a poster child for the drug cost problem at large. The drug’s maker, AbbVie, has viciously fought to keep the active ingredient in Humira (adalimumab) expensive after its original patents ended in 2016 through the filing of additional patents, lawsuits, and deals with generic manufacturers to delay their biosimilar versions from coming out. As a result, the company has continued to raise the price of Humira, and it costs around $72,000 a year. The price-gouging may finally start to die down in 2023, when a flood of biosimilars are expected to reach the market.
